<DOC>
	<DOC>NCT00699023</DOC>
	<brief_summary>The purpose of this study is to determine whether ezetimibe in association with statins is more effective than statins alone on postprandial lipemia in type 2 diabetic patients.</brief_summary>
	<brief_title>Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Type 2 diabetes since at least two years Stable metabolic control (HbA1c&lt;8.0%) for at least six months on diet or diet+oral hypoglycemic drugs (insulin secretagogues or metformin), not to be changed during the study period. BMI&lt;30 kg/m2 and body weight stable during the last six months. Both sexes; only postmenopausal women. LDLcholesterol &gt;130 mg/dl, plasma triglycerides &lt;400 mg/dl. No use of hypolipidemic drugs in the last three months. Patient with renal (serum creatinine &gt;1.5 mg/dl) or hepatic (serum transaminases &gt;three times upper normal values) impairment. Patients with history of cardiovascular disease. Premenopausal women. Any other acute or chronic degenerative disease. Anemia (Hb&lt;12 g/dl). Uncontrolled blood pressure. Use of any drugs able to interfere with the study medications</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>postprandial lipemia</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>